NUTEX HEALTH INC (NUTX)
US67079U3068 - Common Stock
Overall NUTX gets a fundamental rating of 3 out of 10. We evaluated NUTX against 107 industry peers in the Health Care Providers & Services industry. NUTX has a bad profitability rating. Also its financial health evaluation is rather negative. NUTX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year NUTX has reported negative net income.
NUTX had a positive operating cash flow in the past year.
In the past 5 years NUTX always reported negative net income.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
NUTX has a worse Return On Assets (-9.38%) than 69.52% of its industry peers.
NUTX's Return On Equity of -68.06% is on the low side compared to the rest of the industry. NUTX is outperformed by 71.43% of its industry peers.
The Return On Invested Capital of NUTX (5.82%) is better than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.38% | ||
| ROE | -68.06% | ||
| ROIC | 5.82% |
ROA(3y)-41.94%
ROA(5y)-711.14%
ROE(3y)-178.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUTX has a Operating Margin of 9.45%. This is amongst the best in the industry. NUTX outperforms 83.81% of its industry peers.
NUTX has a Gross Margin of 23.24%. This is comparable to the rest of the industry: NUTX outperforms 46.67% of its industry peers.
In the last couple of years the Gross Margin of NUTX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.45% | ||
| PM (TTM) | N/A | ||
| GM | 23.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.93%
GM growth 5Y-21.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NUTX is still creating some value.
Compared to 1 year ago, NUTX has more shares outstanding
NUTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NUTX is higher compared to a year ago.
2.2 Solvency
NUTX has an Altman-Z score of -0.03. This is a bad value and indicates that NUTX is not financially healthy and even has some risk of bankruptcy.
NUTX has a Altman-Z score of -0.03. This is in the lower half of the industry: NUTX underperforms 74.29% of its industry peers.
The Debt to FCF ratio of NUTX is 14.17, which is on the high side as it means it would take NUTX, 14.17 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of NUTX (14.17) is comparable to the rest of the industry.
A Debt/Equity ratio of 4.49 is on the high side and indicates that NUTX has dependencies on debt financing.
NUTX's Debt to Equity ratio of 4.49 is on the low side compared to the rest of the industry. NUTX is outperformed by 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.49 | ||
| Debt/FCF | 14.17 | ||
| Altman-Z | -0.03 |
ROIC/WACC1.13
WACC5.14%
2.3 Liquidity
A Current Ratio of 1.77 indicates that NUTX should not have too much problems paying its short term obligations.
NUTX's Current ratio of 1.77 is fine compared to the rest of the industry. NUTX outperforms 64.76% of its industry peers.
NUTX has a Quick Ratio of 1.74. This is a normal value and indicates that NUTX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.74, NUTX is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
NUTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.13%, which is quite impressive.
NUTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.03%.
NUTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 428.61% yearly.
EPS 1Y (TTM)68.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.67%
Revenue 1Y (TTM)26.03%
Revenue growth 3Y438.49%
Revenue growth 5Y428.61%
Sales Q2Q%25.62%
3.2 Future
Based on estimates for the next years, NUTX will show a very strong growth in Earnings Per Share. The EPS will grow by 35.29% on average per year.
Based on estimates for the next years, NUTX will show a quite strong growth in Revenue. The Revenue will grow by 15.58% on average per year.
EPS Next Y54.14%
EPS Next 2Y51.06%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue Next Year21.68%
Revenue Next 2Y17.99%
Revenue Next 3Y15.58%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NUTX. In the last year negative earnings were reported.
NUTX is valuated quite expensively with a Price/Forward Earnings ratio of 26.72.
NUTX's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.69. NUTX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.72 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NUTX is cheaper than 78.10% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 90.48% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.11 | ||
| EV/EBITDA | 9.16 |
4.3 Compensation for Growth
NUTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NUTX's earnings are expected to grow with 35.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.06%
EPS Next 3Y35.29%
5. Dividend
5.1 Amount
NUTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUTEX HEALTH INC
NASDAQ:NUTX (1/3/2025, 8:00:02 PM)
33.88
-0.84 (-2.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners6.81%
Inst Owner Change76.74%
Ins Owners2.38%
Ins Owner Change0%
Market Cap184.31M
Analysts82.22
Price Target56.44 (66.59%)
Short Float %1.6%
Short Ratio1.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP-11.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-263.14%
Min EPS beat(2)-602.61%
Max EPS beat(2)76.34%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.43%
Min Revenue beat(2)5.5%
Max Revenue beat(2)9.37%
Revenue beat(4)3
Avg Revenue beat(4)3.15%
Min Revenue beat(4)-4.34%
Max Revenue beat(4)9.37%
Revenue beat(8)4
Avg Revenue beat(8)0.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.61%
PT rev (3m)22.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-105.55%
EPS NY rev (1m)5.01%
EPS NY rev (3m)-44.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.81%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)2.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 26.72 | ||
| P/S | 0.63 | ||
| P/FCF | 9.11 | ||
| P/OCF | 8.64 | ||
| P/B | 3.05 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 9.16 |
EPS(TTM)-2.39
EYN/A
EPS(NY)1.27
Fwd EY3.74%
FCF(TTM)3.72
FCFY10.98%
OCF(TTM)3.92
OCFY11.57%
SpS53.68
BVpS11.11
TBVpS5.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.38% | ||
| ROE | -68.06% | ||
| ROCE | 7.44% | ||
| ROIC | 5.82% | ||
| ROICexc | 6.66% | ||
| ROICexgc | 7.32% | ||
| OM | 9.45% | ||
| PM (TTM) | N/A | ||
| GM | 23.24% | ||
| FCFM | 6.93% |
ROA(3y)-41.94%
ROA(5y)-711.14%
ROE(3y)-178.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.93%
GM growth 5Y-21.9%
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.49 | ||
| Debt/FCF | 14.17 | ||
| Debt/EBITDA | 5.9 | ||
| Cap/Depr | 5.9% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | 8.51 | ||
| Cash Conversion | 46.4% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z | -0.03 |
F-Score5
WACC5.14%
ROIC/WACC1.13
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.67%
EPS Next Y54.14%
EPS Next 2Y51.06%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue 1Y (TTM)26.03%
Revenue growth 3Y438.49%
Revenue growth 5Y428.61%
Sales Q2Q%25.62%
Revenue Next Year21.68%
Revenue Next 2Y17.99%
Revenue Next 3Y15.58%
Revenue Next 5YN/A
EBIT growth 1Y347.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year854.81%
EBIT Next 3Y124.74%
EBIT Next 5YN/A
FCF growth 1Y-2.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.83%
OCF growth 3YN/A
OCF growth 5YN/A